Skip to Content
800-533-8762
  • Careers
  • Newsroom
  • Health Care Professionals
  • About Us
  • Contact Us
UPMC
  • Find a Doctor
  • Services
    • Frequently Searched Services
    • Frequently Searched Services
      Allergy & Immunology Behavioral & Mental Health Cancer Ear, Nose & Throat Endocrinology Gastroenterology Heart & Vascular Imaging Neurosciences Orthopaedics
      Physical Rehabilitation Plastic & Reconstructive Surgery Primary Care Senior Services Sports Medicine Telemedicine Transplant Surgery Walk-In Care Weight Management Women’s Health
      See all Services
    • Services by Region
    • Find a UPMC health care facility close to you quickly by browsing by region.
      UPMC in Western Pa. Western Pa. and New York
      UPMC in Central Pa. Central Pa.
      UPMC in North Central Pa. North Central Pa.
      UPMC in Western Md. Maryland & West Virginia
    • See All Services
  • Locations
    • Locations by Type
    • Locations by Type
      UPMC hospitals
      Hospitals
      Physical Therapy
      Physical Therapy
      Urgent care
      Walk-In Care
      UPMC Outpatient Centers
      Outpatient Centers
      UPMC Imaging Services
      Imaging
      Community Health Centers
      Community Health Centers
      See All Locations
    • Locations by Region
    • Locations by Region
      UPMC in Southwest Pa. Southwest Pa.
      UPMC in North Central Pa. North Central Pa.
      UPMC in Northwest Pa and Ny. Northwest Pa. & Western N.Y.
      UPMC in West Central Pa. West Central Pa.
      UPMC in Central Pa. Central Pa.
      UPMC in Western Md. Maryland & West Virginia
    • See All Locations
  • Patients & Visitors
    • Patient & Visitor Resources
    • Patient & Visitor Resources
      Patients and Visitors Resources Pay a Bill Classes & Events Medical Records Health Library Patient Information
      Patient Portals Privacy Information Shared Decision Making Traveling Patients Visitor Information
      Man uses mobile phone
      Pay a Bill
      Nurse reviews medical chart
      Request Medical Records
  • Patient Portals
  • Find Covid-19 updates
  • Schedule an appointment
  • Request medical records
  • Pay a bill
  • Learn about financial assistance
  • Find classes & events
  • Send a patient an eCard
  • Make a donation
  • Volunteer
  • Read HealthBeat blog
  • Explore UPMC Careers
Skip to Content
UPMC
  • Patient Portals
  • For Patients & Visitors
    • Find a Doctor
    • Locations
    • Patient & Visitor Resources
    • Pay a Bill
    • Services
    • More
      • Medical Records
      • Financial Assistance
      • Classes & Events
      • HealthBeat Blog
      • Health Library
  • About UPMC
    • Why UPMC
    • Facts & Stats
    • Supply Chain Management
    • Community Commitment
    • More
      • Financials
      • Support UPMC
      • UPMC Apps
      • UPMC Enterprises
      • UPMC International
  • For Health Care Professionals
    • Physician Information
    • Resources
    • Education & Training
    • Departments
    • Credentialing
  • Careers
  • Contact Us
  • Newsroom
  • UPMC >
  • Media Relations >
  • News Releases >
  • 031219 Targeting Stem Cells Ovarian Ca
Media Relations
News Releases
Central Pa. News
North Central Pa. News
Contact Us
Experts
Community-Focused News
Media Kits
Media RSS
Media Relations
News Releases
Central Pa. News
North Central Pa. News
Contact Us
Experts
Community-Focused News
Media Kits
Media RSS

Chat Keywords List

  • cancel or exit: Stops your conversation
  • start over: Restarts your current scenario
  • help: Shows what this bot can do
  • terms: Shows terms of use and privacy statement
  • feedback: Give us feedback
Continue
Chat with UPMC
RESTART
MENU
CLOSE

Targeting Stem-Like Cells Prevents Ovarian Cancer Recurrence

For Journalists

Erin Hare, Ph.D.
Manager, Science Writing
412-738-1097
HareE@upmc.edu

Cynthia Patton
Director
412-415-6085
pattonc4@upmc.edu

Want to Make an Appointment or Need Patient Information?
Contact UPMC at

1-800-533-8762.

Go to Find a Doctor to search for a UPMC doctor.

Pitt Health Sciences UPMC

3/12/2019

PITTSBURGH – Ovarian cancer is not the most common form of cancer, but it’s among the deadliest. That’s because about 70 percent of cases recur. A new study by researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, Magee-Womens Research Institute (MWRI) and several other collaborating institutions targets the root of recurrence with new drugs aimed at annihilating stem-like ovarian cancer cells.

 

The study, published today in the journal Cell Reports, identifies a new experimental drug, 673A, that specifically kills the stem-like cells that tend to linger after chemotherapy. In a mouse model of ovarian cancer, combined treatment with 673A and chemotherapy resulted in significantly greater survival rates.

 

“You can think of stem-like cells as seeds. They put down roots and grow into a plant,” said Ronald Buckanovich, M.D., Ph.D., professor of medicine at Pitt, director of the Ovarian Cancer Center of Excellence at MWRI, and co-director of the Women’s Cancer Research Center. “I especially like the dandelion analogy. When we treat cancer, we’re essentially mowing the lawn. But the problem is that dandelions always come back.”

 

Chemotherapy kills 90 to 99 percent of cancer cells, but because it leaves the stem-like cells behind, the cancer can come back. All it takes is 11 stem-like cancer cells to form a tumor, Buckanovich said. By comparison, it’s possible to transplant 50,000 non-stem-like cancer cells and not get a tumor.

 

Buckanovich’s drug, 673A, kills these stem-like cells by targeting the ALDH pathway, which the cells rely on to clear the toxins they produce by multiplying so quickly. Treating an ovarian cancer with 673A kills only about 3 to 5 percent of the cells, but since they’re the stem-like cells, that turns out to pack a punch. And, Buckanovich added, it’s not toxic at all to the mice.

 

In mice that were injected with human ovarian cancer cells, 60 percent of the animals treated with both chemotherapy and 673A were cancer-free six months later, compared to 10 percent of the mice treated with chemotherapy alone. 

 

Even more striking, Buckanovich said, 673A was just as effective against chemotherapy-resistant tumors. When mice injected with these tenacious cells were given 673A in conjunction with chemotherapy, nearly two-thirds of them were in remission six months later. By comparison, all of the mice in the chemotherapy-only group died over this same timeframe.

 

Since ovarian cancer commonly develops chemotherapy resistance, this new drug has the potential to improve mortality rates for this deadly cancer.

 

But Buckanovich cautions that more work must done before 673A is ready for market. Right now, it doesn’t last long in the body, and it needs better solubility. It also has yet to be tested in humans. But, more optimistically, he points out that 673A is 10 times as effective at killing stem-like cells than the previous ALDH inhibitor, and its ability to boost the effectiveness of chemotherapy is really encouraging.

 

“It’s like one plus one equals 10,” Buckanovich said. “That was really striking to me, how synergistic the two drugs were. That’s important because it means you can potentially use lower doses and reduce toxicity for patients.”

 

Additional authors on the study include Ilana Chefetz, Ph.D., Kun Yang, Linda Hong, M.D., Ilya Kovalenko, Ph.D., David Karnak, Ph.D., Brandt Huddle, Ph.D., Scott Barraza, Ph.D., Meredith Morgan, Ph.D., Euisik Yoon, Ph.D., David Lombard, M.D., Ph.D., Geeta Mehta, Ph.D., and Scott Larsen, Ph.D., of the University of Michigan; Ekaterina Vinogradova, Ph.D., Radu Suciu and Benjamin Cravatt, Ph.D., of The Scripps Research Institute; Cynthia Morgan, Mikhail Chtcherbinine, Cameron Buchman, Ph.D., and Thomas Hurley, Ph.D., of Indiana University School of Medicine; Andrea Bild, Ph.D., of the University of Utah; Iris Romero, M.D., and Chun-Yi Chiang, M.S., of the University of Chicago; Charles Landen, M.D., of the University of Virginia; Edward Grimley, Ph.D., of Pitt; and Kara Bernstein, Ph.D., of UPMC Hillman.

 

This work was supported by the Department of Defense (OC130322), the National Institutes of Health (5R01CA214567, CA014599, P50CA046592, R01-AA18123, R21-CA198409, R01GM101171, OC140123, ES024872), Foundation for Women’s Cancer and the American Association of Cancer Research (SU2C-AACR-IRG-02-16).
UPMC
200 Lothrop Street Pittsburgh, PA 15213

412-647-8762 800-533-8762

Patients And Visitors
  • Find a Doctor
  • Locations
  • Pay a Bill
  • Patient & Visitor Resources
  • Disabilities Resource Center
  • Services
  • Medical Records
  • No Surprises Act
  • Price Transparency
  • Financial Assistance
  • Classes & Events
  • Health Library
Health Care Professionals
  • Physician Information
  • Resources
  • Education & Training
  • Departments
  • Credentialing
Newsroom
  • Newsroom Home
  • Inside Life Changing Medicine Blog
  • News Releases
About
  • Why UPMC
  • Facts & Stats
  • Supply Chain Management
  • Community Commitment
  • Financials
  • Supporting UPMC
  • HealthBeat Blog
  • UPMC Apps
  • UPMC Enterprises
  • UPMC Health Plan
  • UPMC International
  • Nondiscrimination Policy
Life changing is...
Follow UPMC
  • Contact Us
  • Website/Email Terms of Use
  • Medical Advice Disclaimer
  • Privacy Information
  • Active Privacy Alerts
  • Sitemap
© 2025 UPMC I Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit healthwise.org
Find Care
Providers
Video Visit
Portal Login